Patients with metastatic melanoma have historically had dismal outcomes. The last several years has seen the emergence of effective immune and targeted therapies for metastatic melanoma. Targeted therapies have primarily impacted the 40–50 % of patients with BRAFV600 mutated melanoma. The remainder of patients with advanced melanoma harbor a wide spectrum of mutations other than BRAFV600 that are associated with unique pathophysiological, prognostic, and therapeutic implications. The treatment of this subset of patients is a challenging problem. In recent years, preclinical and early clinical studies have suggested that inhibitors of mitogen activated protein kinase (MAPK) pathway and parallel signaling networks may have activity in treatment of BRAFV600 wild-type (WT) melanoma. In this review, we will discuss available and developing therapies for BRAF WT patients with metastatic melanoma, particularly focusing on molecular targeted options for various genetically defined melanoma subsets.
|Original language||English (US)|
|Number of pages||8|
|Journal||Current oncology reports|
|State||Published - Jan 1 2016|
- BRAF wild-type
ASJC Scopus subject areas